Oct 2 |
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
|
Sep 27 |
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
|
Sep 26 |
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study
|
Sep 26 |
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
|
Sep 3 |
Enanta Pharmaceuticals to Participate in Investor Conferences in September
|
Aug 9 |
Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?
|
Aug 7 |
Enanta Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
|
Aug 5 |
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
|
Aug 5 |
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
|
Aug 5 |
Enanta Pharma GAAP EPS of -$1.07 beats by $0.38, revenue of $18M beats by $0.84M
|